This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Companion Animal Therapeutic Cancer Vaccine Development
Cancer has long been a significant health threat to companion animals. In order to enhance the effectiveness of treatment and reduce the likelihood of adverse reactions, cancer vaccines have come into the focus of many researchers. Cancer vaccines stimulate the animal's immune system against tumor antigens, thereby inhibiting tumor growth and ultimately eradicating tumor cells. BioVenic offers companion animal therapeutic cancer vaccine development services, and we have established multiple technology platforms to meet your various needs.
Fig.1 How do various types of therapeutic cancer vaccines work?1
Our Services
Veterinary Autogenous Cancer Vaccine Development
Ideal antigens for cancer vaccines should be highly immunogenic, highly specific, contain a broad spectrum of diverse tumor-specific antigens (all species or at least most species), and be easily and rapidly accessible. Cancer cells or tissues can be used as a high-quality source of antigens for developing veterinary cancer vaccines.
BioVenic offers autologous cancer vaccine development services for you, where you provide us with fresh samples of excised tumors. Our professionals prepare vaccines using the cancer cells in the tissues to prompt the immune system of the cancerous animal to recognize the dangerous cancer cells in its body.
| Tumor Tissue Excision | At least 2-5 g (1-5 cm3) of non-necrotic fresh tumor tissue that has not been formalin-fixed. |
| Tumor Antigen Extraction | Homogenize tumor samples and extract soluble lysates of tumor cells. |
| Adjuvant Development | Adjuvants are added to increase the immunogenicity of tumor antigens and to maintain their safety as much as possible. |
Veterinary Dendritic Cell Cancer Vaccine Development
Dendritic cells have strong antigen uptake and processing ability, delivering antigen to the initial T cells to initiate adaptive immune response and inducing specific anti-tumor immunity in the animal body. BioVenic has established a platform for the development of dendritic cell vaccines, which are based on the isolation and culture of dendritic cells from the peripheral blood of diseased animals, and the loading of tumor antigens into the dendritic cells.
| Dendritic Cell Culture | Cultured in the sterile laboratory provided by BioVenic to achieve the required number for vaccine preparation. |
| Co-Processing of Tumor Antigens and Dendritic Cells | Tumor whole cell antigen. |
| Synthetic tumor antigen peptides. | |
| Tumor cell DNA or RNA. | |
| Tumor cell-derived exosomes. |
Veterinary Peptide-Based Cancer Vaccine Development
Our peptide-based veterinary subunit vaccine development platform can be customized to your selected epitope to induce robust immune responses against specific tumor antigenic sites. BioVenic also offers a variety of carrier proteins such as heat shock protein (HSP) and keyhole hemocyanin (KLH) that can be fused to peptide antigens to enhance the immunogenicity of your vaccine.
Veterinary Nuclear Acid-Based Cancer Vaccine Development
Nucleic acid vaccines deliver genetic information encoding tumor antigens to the host, and the animal body can then produce antigenic proteins through normal physiological activities, inducing immunocidal effects against cancer cells. BioVenic has established veterinary vaccine development platforms for both DNA and RNA. For more information, please refer to the link below.
| DNA has better stability and exists in the body for a longer period of time. | The prevalence of RNAase. |
| Requires entry into the nucleus to initiate transcription. | Enter the cytoplasm for direct translation and expression of the antigen. |
| A single plasmid DNA can produce multiple copies of mRNA, producing more antigens than a single mRNA molecule. | Only a single mRNA molecule. |
| Potential risk of insertional mutagenesis. | No risk of insertion and integration into the genome. |
Recombinant Vectored Vaccine Development
In recombinant vectored vaccine development, tumor-associated genetic material is delivered into the body of cancer-afflicted animals through a virus or bacterial "vector," rather than directly injecting naked DNA. BioVenic offers a variety of virus and bacterial vector options, leveraging the biological characteristics of these vectors to enhance the delivery efficiency of tumor DNA into target cells, thereby improving the success and precision of gene delivery. Complementary services for the development of recombinant vectored veterinary vaccines are also provided by BioVenic. For more details, please click on the link below.
- Recombinant Vectored Veterinary Vaccine Development
| Types of Common Virus Vector | Types of Common Bacterial Vector |
|---|---|
| Lentivirus | Lactobacillus spp. |
| Adenovirus | Salmonella spp. |
| Adeno-associated virus (AAV) | Listeria monocytogenes |
Why Choose Us?
- Broad-spectrum anticancer available for the development of veterinary therapeutic cancer vaccines containing multiple immune system antigen targets.
- Multiple veterinary vaccine development technology platforms are available.
- Precise epitopes for the one-shot killing of animal tumor antigens.
- Formulation optimization to enhance immune responses against multiple animal cancer types.
Many companion animals such as dogs and cats are greatly affected by cancer in later life or by environmental factors. BioVenic has accumulated a wealth of experience in the research and development of companion animal cancer vaccines. No matter what technological platform you would like to start from, please contact us for more information!
Reference
- Liu, Jian, et al. "Cancer vaccines as promising immuno-therapeutics: platforms and current progress." Journal of Hematology & Oncology 15.1 (2022): 28.